drugset / Trial / NCT02502786
Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma
Phase 2
Active not recruiting
46 enrolled
Memorial Sloan Kettering Cancer Center
Children's Hospital Los Angeles · collabM.D. Anderson Cancer Center · collabY-mAbs Therapeutics · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find out what effect an antibody called Humanized 3F8 (Hu3F8) and a drug called GM-CSF have on the patient and whether it can keep the patient in remission longer and/or prevent recurrence of the disease.
Timeline
- Start
- 2015-07
- Primary completion
- 2026-07
- Completion
- 2026-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Naxitamab | Monoclonal antibody | 2.4 mg/kg | — |
| Subject | sargramostim | Protein / enzyme biologic | — | Subcutaneous |